2024 Pancreatic Cancer Research Update
Dr. Edna Cukierman and her team at Fox Chase Cancer Center have made significant progress in their AHEPA-funded project to develop drugs that intercept pancreatic cancer development. Their work, supported by AHEPA since 2018, focuses on targeting cancer-associated fibroblasts (CAFs) in the pancreatic tumor microenvironment, particularly synaptic proteins normally found in the brain that appear in pancreatic cancer lesions. This research has generated six manuscripts and led to thirteen invited presentations at scientific conferences during 2024.
The team has successfully narrowed down from 22 to 3 most effective antibodies that can transform tumor-promoting CAF/ECM units into tumor-suppressive ones. They’re currently producing 150 milligrams of the best candidate for further testing. Additionally, they’ve developed new algorithmic tools for analyzing collagen matrix quality and created a mouse model lacking expression of the key receptor. These advances are being prepared for publication as the research moves toward potential human clinical trials.
In a significant recognition of her contributions to pancreatic cancer research, Dr. Cukierman was named to the newly created Marvin and Concetta Greenberg Chair in Pancreatic Cancer Research at Fox Chase Cancer Center. This endowed position acknowledges her pioneering work in understanding the tumor microenvironment and developing innovative approaches to combat pancreatic cancer. The appointment strengthens her leadership role as Co-Director of the Marvin and Concetta Greenberg Pancreatic Cancer Institute, further enabling her team to pursue groundbreaking research in this critical field. The Fifth District AHEPA Cancer Research Foundation extends its warmest congratulations to Dr. Cukierman on this well-deserved appointment, recognizing it as a testament to her dedication and scientific excellence in the fight against pancreatic cancer.
While pancreatic cancer survival rates have slightly improved from 12% to 13%, new treatments remain urgently needed as most patients are diagnosed at advanced stages with limited options. Dr. Cukierman’s team has presented their AHEPA-supported findings at prestigious institutions worldwide, including conferences in the United States and Australia. The 30+ year relationship with AHEPA continues to be instrumental in advancing this critical pancreatic cancer research.
Help us continue to support the progress towards reducing cancer suffering. Mark your calendars for November 8, 2025 at the Pines Manor, where we celebrate and announce our newest research recipients.
